Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice
The incretin receptor agonists semaglutide and tirzepatide have transformed the medical management of obesity. The neural mechanisms by which incretin analogs regulate appetite remain incompletely understood, and dissecting this process is critical for the development of next-generation antiobesity drugs that are more targeted and tolerable. Moreover, the physiologic functions of incretins in appetite regulation and […]
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Glucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being largely dependent on the induction of weight loss. In more recent years, the role of this peptide beyond metabolism has progressively […]
Ethics of Lifestyle Counsel Alone in a GLP-1 Era
This Viewpoint explores how ethical principles may guide pediatricians’ approach to lifestyle counseling and pediatric obesity care in the era of glucagon-like peptide-1 (GLP-1) receptor agonists.
A preview of this year’s federal employee health benefits open season
Interview transcript: Jared Serbu All right, Tammy, the time is approaching very quickly here. November 10th is the start of Open Season. Not quite time for folks to be actually registering their decisions yet, but what should we be doing to prepare? Tammy Flanagan Yeah, it’s not too early to start looking at some things […]
🐢 Weight loss drug is now the world’s top-selling medicine + 8 more stories
In the last 4 days ChatGPT read 120105 top news stories. After removing previously covered events, there are 9 articles with a significance score over 5.9. [6.2] Eli Lilly’s weight loss and diabetes drug becomes world’s best-selling medicine — statnews.com (+22) Eli Lilly’s diabetes and obesity drug, tirzepatide, has surpassed Merck’s cancer therapy Keytruda to […]
American Heart Association: Thank Ozempic For Less Type 2 DIabetes
At the upcoming American Heart Association meeting, participants will learn of the epidemiological results of 63,656 military veterans with Type 2 diabetes in the Million Veteran Program who took GLP-1 receptor agonists (semaglutide – “Wegovy”, dulaglutide – “Trulicity”, etc.). The survey analysis found that those who also changed their lifestyle habits had a 50% lower […]
Viking Therapeutics Could Be Pharma’s Next Big Buyout Target
Quick Read GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809’s NASH success. Viking is advancing dual therapies amid a $150 billion obesity opportunity. With a recent big buyout offer for a rival not as far along as Viking, the biotech could draw a big pharma bid next. […]
AI’s Power Problem
In this podcast, Motley Fool analysts Nick Sciple, Seth Jayson, and Tim Beyers: Discuss the vast sums being invested in power infrastructure, and whether current plans will be enough to meet demand. Cover the opportunities and complications from filling the void with existing and emerging nuclear technology. Play a nuclear-themed game of Faker or Breaker. […]
GLP-1 RA May Cut Surgery Risk in Patients With IBD
Use of GLP-1 RA in patients with IBD and obesity and/or T2D is significantly associated with weight loss and a reduced risk for surgery. Medscape Medical News
With 800 million people living with obesity worldwide, Warsaw’s Holi secures €3 million to expand its digital treatment platform
Holi, a Polish HealthTech startup building a digital obesity clinic, has raised €3 million in Seed funding to enter new European markets and further develop its data-driven care platform. The round led by 4growth VC (Poland) with participation from YZR Capital (Germany), Heartfelt Capital (Germany) and a group of business angels. “Obesity treatment requires continuity […]